We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$92.4M
Cap. Flow
+$88.5M
Cap. Flow %
24.56%
Top 10 Hldgs %
19.65%
Holding
155
New
60
Increased
18
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$9.64M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$6.47M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$6.31M
4
CDNA icon
CareDx
CDNA
+$6.31M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
+$6.28M

Top Sells

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$15.5M
2
GNPX icon
Genprex
GNPX
+$6.81M
3
ANAB icon
AnaptysBio
ANAB
+$5.62M
4
COGT icon
Cogent Biosciences
COGT
+$4.86M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 82.98%
2 Financials 2.24%
3 Consumer Staples 0.95%
4 Industrials 0.89%
5 Technology 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
76
Coherus Oncology
CHRS
$196M
$2M 0.55%
136,623
-80,302
-37% -$1.36M
PRDS
77
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.99M 0.55%
+200,000
New +$2.07M
JYAC
78
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.97M 0.55%
200,000
– –
KA
79
DELISTED
Kineta, Inc. Common Stock
KA
$1.97M 0.55%
+15,528
New +$2.1M
DNTH icon
80
Dianthus Therapeutics
DNTH
$6.09B
$1.95M 0.54%
+10,274
New +$1.73M
HLMN icon
81
Hillman Solutions
HLMN
$1.79B
$1.93M 0.53%
+192,314
New +$2.01M
HAE icon
82
Haemonetics
HAE
$4B
$1.89M 0.53%
17,044
-9,100
-35% -$1.13M
TMPO
83
DELISTED
Tempo Automation Holdings, Inc. Common Stock
TMPO
$1.88M 0.52%
+189,000
New +$2.08M
CSTL icon
84
Castle Biosciences
CSTL
$979M
$1.87M 0.52%
27,365
-34,626
-56% -$2.6M
ACET icon
85
Adicet Bio
ACET
$74.7M
$1.86M 0.52%
+8,893
New +$2.04M
DCOY
86
Decoy Therapeutics
DCOY
$2.09M
$1.85M 0.51%
+35
New +$2.01M
EIGR
87
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.75M 0.49%
6,583
– –
CTIC
88
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.71M 0.48%
588,992
– –
STIM icon
89
Neuronetics
STIM
$166M
$1.7M 0.47%
+137,500
New +$2.11M
BWAY
90
Brainsway
BWAY
$622M
$1.62M 0.45%
+359,012
New +$1.55M
XGN icon
91
Exagen
XGN
$166M
$1.51M 0.42%
+86,475
New +$1.54M
WGS icon
92
GeneDx Holdings
WGS
$2.3B
$1.49M 0.41%
+3,030
New +$1.58M
ONCT
93
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.47M 0.41%
8,814
-11,769
-57% -$1.56M
GRI
94
GRI Bio
GRI
$2.6M
– –
0
– –
LRMR icon
95
Larimar Therapeutics
LRMR
$432M
$1.36M 0.38%
93,261
– –
TNGX icon
96
Tango Therapeutics
TNGX
$4.41B
$1.33M 0.37%
120,000
– –
BURU
97
DELISTED
NUBURU INC
BURU
$1.27M 0.35%
+643
New +$1.35M
VRAY
98
DELISTED
ViewRay, Inc.
VRAY
$1.26M 0.35%
+289,114
New +$1.4M
GIGGU
99
DELISTED
GigCapital4, Inc. Unit
GIGGU
$1.23M 0.34%
+125,000
New +$1.26M
BLSA
100
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$1.06M 0.29%
100,000
– –
2 3
4
5 6

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Altium Capital Management held 155 positions worth $360M, up 34% from $268M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Altium Capital Management deployed $88.5M of net new capital in Q1 2021, opening 60 new positions and adding to 18 existing holdings. Its largest new stake was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Opus Genetics, an estimated $15.5M trimmed.

  • Altium Capital Management's largest Q1 2021 buy was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
  • Altium Capital Management added most to Verrica Pharmaceuticals in Q1 2021, an estimated $6.28M increase.
  • Altium Capital Management's biggest Q1 2021 reduction was Opus Genetics, cutting an estimated $15.5M.
  • Altium Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $5.62M.
  • Altium Capital Management's ten largest holdings make up 20% of its $360M portfolio in Q1 2021.
  • Altium Capital Management opened 60 new positions and closed 31 in Q1 2021.
  • Altium Capital Management's portfolio value rose 34% quarter-over-quarter to $360M.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.